Physician profile
John Lee Cossu
NPI 1609954643
$258.64
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.59 · 2020: $16.19 · 2021: $169 · 2022: $40.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $61.93 | 2021 | |
| Glaxosmithkline, LLC. | $35.40 | 2021-2022 | |
| Amgen INC. | $34.21 | 2021-2022 | |
| Antares Pharma, INC. | $19.64 | 2019 | |
| Novo Nordisk INC | $18.76 | 2021 | |
| Dexcom, INC. | $18.25 | 2021 | |
| Lilly USA, LLC | $16.19 | 2020 | |
| Abbott Laboratories | $15.75 | 2021 | |
| Genentech USA, INC. | $13.95 | 2019 | |
| Acerus Pharmaceuticals Corporation | $13.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.44 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cossu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.